Gupta Salil, Abbot A K, Srinath R, Tewari A K, Gupta Aditya, Gorthi S P, Narayanan C S, Totlani S I, Sirohi Y S, Anadure Ravi
Professor & Head (Neurology), Army Hospital (R&R), New Delhi, India.
Graded Specialist (Medicine), Military Hospital Partapur, India.
Med J Armed Forces India. 2018 Apr;74(2):120-125. doi: 10.1016/j.mjafi.2017.03.010. Epub 2017 May 18.
Haematoma expansion due to raised blood pressure in spontaneous intracerebral haemorrhage may determine outcome. The aim of this study was to determine safety and efficacy of lowering blood pressure in acute spontaneous intracerebral haemorrhage.
This open label, multicentric trial randomized patients ≥18 years with spontaneous intracerebral haemorrhage with no secondary cause within 72 h of onset to tight BP control arm where treatment was initiated if mean arterial pressure (MAP) was ≥115 mm of Hg and conventional BP control arm where treatment was initiated if MAP was ≥130 mm of Hg. The MAP was maintained in the respective arm for another 72 h after which both arms had MAP below 115 mm of Hg. Primary outcome was modified Rankin Scale at 90 days.
118 patients, 59 in each arm were included. Follow up was available for all. Baseline characteristics were similar. At 90 days there was no significant difference between median mRS between the two arms. Odds Ratio for "poor outcome" (mRS 3-6) in the tight control arm (safety of the intervention) against "good outcome" (mRS 0-2) was not significant (OR 0.70 [95% CI 0.34-1.47] = 0.35). Efficacy of the intervention in the form of Odds Ratio for "good outcome" in the tight control arm was not significant (OR 1.43 [95% CI 0.68-2.99], = 0.35).
In patients with spontaneous intracerebral haemorrhage who present within 72 h of the onset of symptoms, MAP can be safely lowered if it crosses 115 mm of Hg but it does not improve clinical outcome.
自发性脑出血时血压升高导致的血肿扩大可能决定预后。本研究的目的是确定降低急性自发性脑出血患者血压的安全性和有效性。
这项开放标签、多中心试验将年龄≥18岁、在发病72小时内无继发原因的自发性脑出血患者随机分为严格血压控制组(如果平均动脉压(MAP)≥115mmHg则开始治疗)和传统血压控制组(如果MAP≥130mmHg则开始治疗)。在各自的组中将MAP维持另外72小时,之后两组的MAP均低于115mmHg。主要结局是90天时的改良Rankin量表评分。
纳入118例患者,每组59例。所有患者均获得随访。基线特征相似。90天时,两组之间的中位改良Rankin量表评分无显著差异。严格控制组中“不良结局”(改良Rankin量表评分3 - 6)与“良好结局”(改良Rankin量表评分0 - 2)相比的优势比(干预的安全性)不显著(优势比0.70 [95%置信区间0.34 - 1.47],P = 0.35)。严格控制组中以“良好结局”优势比形式表示的干预效果不显著(优势比1.43 [95%置信区间0.68 - 2.99],P = 0.35)。
对于症状出现72小时内就诊的自发性脑出血患者,如果MAP超过115mmHg,可以安全地降低血压,但这并不能改善临床结局。